Bristol Renounces Late-Listed Patents Under FTC Settlement
Executive Summary
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
You may also be interested in...
180-Day Exclusivity Ruling On Cosopt Signals Need For Strong Patent Challenges
FDA's decision that Hi-Tech forfeited its generic exclusivity for Merck's ophthalmic Cosopt (dorzolamide/timolol) means that firms may need to give more weight to the strength of their patent challenges as they make filing decisions in the future
180-Day Exclusivity Ruling On Cosopt Signals Need For Strong Patent Challenges
FDA's decision that Hi-Tech forfeited its generic exclusivity for Merck's ophthalmic Cosopt (dorzolamide/timolol) means that firms may need to give more weight to the strength of their patent challenges as they make filing decisions in the future
Organon Settles Remeron Antitrust Cases; Injunction Follows Bristol Model
The proposed settlement of a patent listing case against Organon follows the model of the injunction negotiated by Bristol-Myers Squibb and the Federal Trade Commission a year ago